Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TAP Biosystems Presents New Data on 3D Cell Culture Research

Published: Monday, January 20, 2014
Last Updated: Sunday, January 19, 2014
Bookmark and Share
Discussing the application of RAFT 3D models in oncology, toxicology and neuroscience cell-based screening programmes.

TAP Biosystems has announced that it will be giving two presentations on its RAFT 3D cell culture system at the Society for Laboratory Automation and Screening (SLAS) Conference in San Diego.

Senior applications specialists will discuss how 3D models are being used to improve oncology, neuroscience and toxicology research programmes and present the latest research data.

TAP is presenting a lunchtime tutorial entitled: “Use of 3D cell culture in oncology research” which will be hosted by Dr Grant Cameron, TAP Biosystems’ RAFT Development Director in room 28a between 12.30-1.15pm on Monday January 20th.

The presentation will include details on how 3D cultures with tissue-like, physiologically relevant concentrations of cells and collagen are generated without using complex chemistry, cross linking agents or extended culture periods.

The talk will provide new data showing how cancer cell lines cultured with the RAFT system are used to generate dose response curves, as well as study cell signalling, target modulation and mitochondrial function. It will also focus on new data showing the use of human primary and iPSC hepatocytes with the RAFT system.

Spaces at this tutorial are limited and researchers wanting to attend should click the link http://www.tapbiosystems.com/RAFT_webinar/SLAStutorial.asp to register.

Also on Monday January 20th there will be a podium presentation from 3.00-3.30pm by Dr Rosemary Drake, TAP Biosystems’ Chief Scientific Officer as part of the scaling up microfluidics diagnostics session.

Entitled “Collagen Engineering for Simple, Consistent Production of Complex Model Tissues for Drug Discovery - Stem Cell Niche in a Dish”, it will show how the RAFT process generates defined, spatial assembly of cells and extracellular matrix simply and consistently, and will discuss the importance and influence of the microenvironment on cell behaviour, including iPSC. It will describe engineering the stem cell niche of the cornea, by creating topography in a rapid one step process. It will also discuss methods and tools for aligning the collagen matrix and cells to produce more realistic neural system models and will illustrate the wide applicability of RAFT 3D cell cultures across drug discovery research and screening.

Dr Grant Cameron, TAP Biosystems’ RAFT Development Director commented: “3D cell culture permits more complex systems to be studied and provides greater insights into complex cellular interactions and more physiologically relevant data than conventional 2D systems. Our presentations at SLAS explain how RAFT generated 3D constructs with simple or complex topography can be rapidly produced in standard plates at a scale appropriate for drug discovery. Researchers looking to incorporate reproducible 3D cell cultures into their oncology or toxicology cell-based screening programmes for example, should attend our presentations at SLAS or come and see the simple to use, RAFT system in action on Booth 520.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!